Despite a dramatic reduction in restenosis and target vessel revascularization rates by drug-eluting stents (DES), conflicting concerns have been raised over the risk of late DES thrombosis when compared to bare-metal stents. Certainly, the heterogeneity of DES results from the introduction of a great variety of new DES types with diverse efficacy and safety parameters. Furthermore, there is a steady increase in DES availability without parallel and robust data from randomized clinical trials. Thus, the postulated class effect of DES should be regarded as non-obligatory. This article is based on 110 randomized DES trials performed on 72 305 patients. Current status of DES and guidelines for DES implantation in various clinical scenarios are discussed.